Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for SAB Biotherapeutics, Inc. (SABS : NSDQ)

• Company Description    SAB Biotherapeutics Inc. is a clinical-stage biopharmaceutical company advancing a new class of immunotherapies leveraging fully human polyclonal antibodies. It produces natural, specifically targeted, high-potency, human polyclonal immunotherapies. SAB Biotherapeutics Inc., formerly known as Big Cypress Acquisition Corp., is based in SIOUX FALLS, S.D. Number of Employees: 63

• Price / Volume Information    Yesterday's Closing Price: $2.10 Daily Weekly Monthly 20 Day Moving Average: 83,464 shares Shares Outstanding: 10.41 (millions) Market Capitalization: $21.86 (millions) Beta: 0.54 52 Week High: $5.01 52 Week Low: $1.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -3.67% -6.09% 12 Week 19.32% 8.67% Year To Date -44.65% -50.79%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 777 W 41st St Suite 401 - Miami Beach,FL 33140 USA ph: 605-679-6980 fax: - kgardner@lifesciadvisors.com http://www.sabbiotherapeutics.com

• General Corporate Information    Officers Samuel J. Reich - Chairman of the Board and Chief Executive Officer Eddie J. Sullivan - President Christoph Bausch - Chief Operating Officer Lucy To - Chief Financial Officer Erick Lucera - Director Peer Information SAB Biotherapeutics, Inc. (CORR.) SAB Biotherapeutics, Inc. (RSPI) SAB Biotherapeutics, Inc. (CGXP) SAB Biotherapeutics, Inc. (BGEN) SAB Biotherapeutics, Inc. (GTBP) SAB Biotherapeutics, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 78397T202 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/25 Next Expected EPS Date: 11/05/25 Share - Related Items Shares Outstanding: 10.41 Most Recent Split Date: 1.00 (0.10:1) Beta: 0.54 Market Capitalization: $21.86 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.72 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.56 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 4.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.62 Price/Cash Flow: - Price / Sales: 7.86 EPS Growth vs. Year Ago Period: -37.97% vs. Previous Quarter: -94.64% Sales Growth vs. Year Ago Period: -62.35% vs. Previous Quarter: -% ROE 06/30/25 - -153.92 03/31/25 - -105.14 12/31/24 - -84.31 ROA 06/30/25 - -89.16 03/31/25 - -69.24 12/31/24 - -58.99 Current Ratio 06/30/25 - 0.87 03/31/25 - 1.69 12/31/24 - 2.98 Quick Ratio 06/30/25 - 0.87 03/31/25 - 1.69 12/31/24 - 2.98 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - -32,221.74 03/31/25 - -9,067.72 12/31/24 - -2,579.80 Book Value 06/30/25 - 1.29 03/31/25 - 2.30 12/31/24 - 2.81 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - 0.27 03/31/25 - 0.15 12/31/24 - 0.13 Debt-to-Capital 06/30/25 - 21.03 03/31/25 - 13.14 12/31/24 - 11.20

Powered by Zacks Investment Research ©